Prelude Therapeutics Stock Alpha and Beta Analysis
| PRLD Stock | USD 2.45 0.22 9.87% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Prelude Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Prelude Therapeutics over a specified time horizon. Remember, high Prelude Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Prelude Therapeutics' market risk premium analysis include:
Beta 0.53 | Alpha 2.68 | Risk 21.52 | Sharpe Ratio 0.12 | Expected Return 2.53 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Prelude Therapeutics Backtesting, Prelude Therapeutics Valuation, Prelude Therapeutics Correlation, Prelude Therapeutics Hype Analysis, Prelude Therapeutics Volatility, Prelude Therapeutics History and analyze Prelude Therapeutics Performance. Prelude Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Prelude Therapeutics market risk premium is the additional return an investor will receive from holding Prelude Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Prelude Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Prelude Therapeutics' performance over market.| α | 2.68 | β | 0.53 |
Prelude Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Prelude Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Prelude Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Prelude Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Prelude Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Prelude Therapeutics shares will generate the highest return on investment. By understating and applying Prelude Therapeutics stock market price indicators, traders can identify Prelude Therapeutics position entry and exit signals to maximize returns.
Prelude Therapeutics Return and Market Media
The median price of Prelude Therapeutics for the period between Mon, Sep 29, 2025 and Sun, Dec 28, 2025 is 1.54 with a coefficient of variation of 24.97. The daily time series for the period is distributed with a sample standard deviation of 0.4, arithmetic mean of 1.61, and mean deviation of 0.24. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 9375 shares by Huang Jane of Prelude Therapeutics subject to Rule 16b-3 | 10/03/2025 |
2 | Real time pattern detection on Prelude Therapeutics Incorporated stock - Trade Exit Summary Detailed Earnings Play Alerts - newser.com | 10/22/2025 |
3 | Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors | 11/04/2025 |
4 | Why Prelude Therapeutics Is Up 14.3 percent After Incyte Backs 25M Private Placement - And Whats Next | 11/05/2025 |
5 | Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 11/12/2025 |
6 | PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm | 11/19/2025 |
7 | Beat the Market the Zacks Way Goldman Sachs, Micron, Prelude in Focus - TradingView | 11/24/2025 |
8 | Prelude Therapeutics Incorporateds 66 percent Share Price Plunge Could Signal Some Risk | 12/03/2025 |
9 | Why Prelude Therapeutics Incorporated stock attracts global investors - 2025 Dividend Review Daily Profit Maximizing Tips - Blm Sonu Canavar | 12/18/2025 |
10 | Prelude Therapeutics Stock Price Up 2.1 percent Should You Buy | 12/26/2025 |
About Prelude Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Prelude or other stocks. Alpha measures the amount that position in Prelude Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Interest Debt Per Share | 0.24 | 0.25 | Revenue Per Share | 0.0831 | 0.0738 |
Prelude Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Prelude Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Prelude Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Prelude Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Prelude Therapeutics. Please utilize our Beneish M Score to check the likelihood of Prelude Therapeutics' management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Prelude Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Prelude Therapeutics Backtesting, Prelude Therapeutics Valuation, Prelude Therapeutics Correlation, Prelude Therapeutics Hype Analysis, Prelude Therapeutics Volatility, Prelude Therapeutics History and analyze Prelude Therapeutics Performance. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Prelude Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.